Skip to main content
. 2015 Jun 3;92(Suppl 6):75–86. doi: 10.4269/ajtmh.14-0544

Figure 2.

Figure 2.

Proportion of (A) poor quality artemisinin-containing antimalarials (ACAs) by region based on artemisinin component only, and (B) poor quality artemisinin-based combination therapies (ACTs) by region based on artemisinin component and partner drug for selected ACTs (poor quality defined as less than 85% or greater than 115% of stated API).